On July 18th, Zhao Bei's funds under the Industrial Bank Ruixing Fund announced the second quarter report for 2024. As of the end of the second quarter, Zhao Bei's managed assets were close to 20 billion yuan, with the Industrial Bank Ruixing Frontier Medical Stock Fund having assets of around 11.493 billion yuan and a net value growth rate of -6.71% during the reporting period. The Industrial Bank Ruixing Healthcare Stock Fund had assets of around 3.222 billion yuan and a net value growth rate of -9.45% during the reporting period. Specifically, the Industrial Bank Ruixing Frontier Medical Stock Fund did not perform well over the past 6 months, 1 year, and 3 years, with losses of 14.95%, 23.58%, and 47.93% respectively. However, the fund had a return rate of nearly 70% over the past 5 years. As of the end of the second quarter, the top ten holdings of the Industrial Bank Ruixing Frontier Medical Stock Fund were Hengrui Medicine, Mindray Medical, Dong-E-E-Jiao, Colen Pharmaceutical, CR Sanjiu, CR Double Crane, Xinte Tai, Huadong Medicine, Yuyue Medical, and Kintor Pharmaceutical. Among these, Yuyue Medical, Kintor Pharmaceutical, and Xinte Tai were new top holdings in the second quarter, while Elion Ophthalmology, Chia Tai Tianqing, and Baiyang Pharmaceuticals dropped out of the top ten holdings. Zhao Bei stated that in the second quarter, the fund continued to adjust its allocation strategy in line with industry and market trends. It made adjustments in sectors like innovative drugs, traditional Chinese medicine, medical equipment, and consumer healthcare, as well as rebalancing in specific areas and individual stocks. Zhao Bei pointed out that since June, a series of documents from the National Medical Insurance Administration on price management for retail pharmacies and a special action on drug price comparisons has caused market concerns and led to a significant pullback in pharmacies and traditional Chinese OTC sectors. However, this year's Government Work Report for the first time mentioned accelerating the development of innovative drugs and other industries, showing clear support for the innovative drug sector. Records show that Zhao Bei has 15 years of experience in the securities industry, having joined Industrial Bank Ruixing in 2010. She currently holds positions as the deputy general manager of the research department, investment director, and fund manager. She is a well-known pharmaceutical fund manager in the market, once being dubbed the "Goddess of Pharmaceuticals," with assets under management exceeding 30 billion yuan at one point.